PUBLIC NOTICE

Pursuant to 42 CFR § 447.205, the Oklahoma Health Care Authority (OHCA) is required to give public notice of any significant proposed change in methods and standards for setting payment rates for services in the SoonerCare program. The state plan amendment was presented at the Tribal Consultation meeting on November 5, 2019 at 11:00 AM at the OHCA offices located at 4345 N. Lincoln Blvd., OKC, OK 73105 in the OHCA Board Room.

High Investment Drugs, Effective date: April 1, 2020, contingent upon CMS approval.

Proposed revisions to the Oklahoma Medicaid state plan clarify the methodology for reimbursement of high investment drugs. Payment for high investment drugs that are used to treat members during an inpatient admission or outpatient hospital visit will be the lower of: (1) the hospital's actual acquisition cost; (2) the Wholesale Acquisition Cost (WAC); (3) the Average Sales Price (ASP) + 6% Medicare Part B, if available; or, (4) billed charges.

This proposed revision will require hospitals to bill for high-investment drugs on a separate outpatient hospital claim. The high-investment drug charges and any other inpatient/outpatient services rendered shall not appear on the same hospital claim.

This proposal is budget neutral.

The proposed changes may be viewed and receive written comments on the agency's website at www.okhca.org/PolicyBlog. Persons wishing to present their views in writing or obtain copies of the proposed changes may do so at the following address: Federal Authorities Unit, Oklahoma Health Care Authority. 4345 N. Lincoln Blvd., Oklahoma City, Oklahoma, 73105, or by email at federal.authorities@okhca.org. Written and/or oral comments or requests for copies of the proposed changes will be accepted during regular business hours by contacting the OHCA as indicated. Comments submitted will be available for review by the public Monday – Friday, 9:00 AM to 4:30 PM, at OHCA located at the above address or online at www.okhca.org/PolicyBlog.